Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979501 | 0.89 | L3MBTL1 (0.53) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL7984504 | 0.88 | CACNA1G (0.50) | MMP13MAPTDRD2TSHRSMN1; SMN2 | |
| SCHEMBL7977871 | 0.86 | HDAC6 (0.49) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL7974402 | 0.85 | CACNA1G (0.48) | MAPTTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6706798 | 0.84 | MAPT (0.55) | MMP13MAPTDRD2NR1H4PTGER4 | |
| SCHEMBL7981151 | 0.84 | CACNA1G (0.48) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1417419 | 0.83 | KMT2A (0.53) | MMP13SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6765613 | 0.83 | MEN1 (0.52) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1418031 | 0.82 | DRD4 (0.55) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5696948 | 0.82 | MMP13 (0.53) | MMP13MAPTDRD2NR1H4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | MMP13 1/4885MAPT 2199/4885DRD2 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.